News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Dec 6, 2024

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Dec 2, 2024

  Insmed To Present at December 2024 Investor Conferences
• Nov 7, 2024

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Nov 6, 2024

  Insmed To Present at November 2024 Investor Conferences
• Oct 31, 2024

  Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update
• Oct 24, 2024

  Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List
• Oct 23, 2024

  Insmed Unites Across Communities Around the World During Third Annual Global Day of Good
• Oct 17, 2024

  Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024
• Oct 8, 2024

  New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results
• Oct 4, 2024

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Sep 6, 2024

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Aug 8, 2024

  Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update
• Aug 2, 2024

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Jul 29, 2024

  Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024
• Jul 5, 2024

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Jul 3, 2024

  Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference
• Jun 27, 2024

  Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025
• Jun 7, 2024

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Jun 5, 2024

  Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference
• May 30, 2024

  Insmed to Host Commercial Webinar on June 4, 2024
• May 30, 2024

  Insmed Announces Pricing of $650 Million Public Offering of Common Stock
• May 28, 2024

  Insmed Announces Proposed $500 Million Public Offering of Common Stock
• May 28, 2024

  Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
• May 27, 2024

  Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
• May 20, 2024

  Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session
• May 9, 2024

  Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
• May 7, 2024

  Insmed To Present at the BofA Securities Health Care Conference 2024
• May 3, 2024

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Apr 25, 2024

  Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
• Apr 5, 2024

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Mar 27, 2024

  Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference
• Mar 5, 2024

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Feb 29, 2024

  Insmed To Present at Three March Conferences
• Feb 28, 2024

  Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health
• Feb 22, 2024

  Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
• Feb 8, 2024

  Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024
• Feb 2, 2024

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Jan 5, 2024

  Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
• Jan 4, 2024

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Jan 2, 2024

  Insmed To Present at the 42nd Annual J.P. Morgan Healthcare Conference
• Dec 5, 2023

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Nov 29, 2023

  Insmed To Present at the Nasdaq 49th Investor Conference
• Nov 8, 2023

  Insmed To Present at Two November Conferences
• Nov 3, 2023

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Nov 2, 2023

  Insmed Holds Second Annual Global Day of Good to Benefit Communities Across the Globe
• Oct 26, 2023

  Insmed Ranks No. 1 on Science's 2023 Top Biopharma Employers List
• Oct 26, 2023

  Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update
• Oct 24, 2023

  Insmed and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI
• Oct 12, 2023

  Insmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023
• Oct 6, 2023

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download